Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC).

e14567 Background: The mTOR pathway has a central role in HCC not only in the tumor growth but also in the insulin driven hepatocarcinogenesis and is reported activated in 40-50% of HCC patients. T...